Articles with keyword mutation

MOLECULAR TARGETS IN LUNG CANCER: CURRENT STATUS (E.N. Imyanitov)

lung cancer, mutation, smoking, tumor, inhibitor

The role of liquid biopsy in the choice of tactics For the treatment of non-small cell lung cancer (K.K. Laktionov, A.M. Kazakov, K.A. Sarantseva, E.V. Reutova, A.L. Arzumanyan, N.M. Moskalyuk)

non-small cell lung cancer, fluid biopsy, mutation profile, minimal residual disease

BIOLOGY CHRACTERISTICS IN UROLOGICAL CANCERS DEVELOPEMENT (P.S. Borisov, R.V. Orlova, E.E. Topuzov)

urothelial carcinoma, muscle invasive bladder cancer (MIBC), non-muscle invasive bladder cancer (NMBC), FGFR3, TP53, oncogene, mutation load, genetic profiling.

MOLECULAR-ORIENTED AND PRECISION CANCER THERAPY – THE PRESENT AND FUTURE ASPECTS (D.B. Korman)

cancer, molecular-oriented drugs, precision therapy, sequencing DNA, tumor-associated mutations, tumor-type agnostic therapy.

Fundamental oncology in 2015: a review of the most interesting discoveries (E.N. Imyanitov)

сancer immunotherapy, fundamental oncology, microsatellite instability, acquired cancer resistance, circulating tumor DNA, cancer hormonotherapy, KRAS mutation

Clinical experience of afatinib application In non-cell lung cancer of lung. Ii line of therapy (L.M. Kogoniya, E.V. Markarova, G.A. Stashuk, V.E. Shikina)

lung cancer, adenocarcinoma, non-small cell lung cancer, EGFR mutation, chemotherapy, targeted therapy, efficacy, elderly, side effects

EVOLUTION OF SCREENING FOR PROSTATE CANCER (A.I. Novikov)

prostate cancer, screening, prostate-specific antigen (PSA), prostate health index, multiparameter magnetic-resonance tomography (mpMRI), biomarkers (Select MDX, HOXX6, DLX1), genetic mutations (BRCA1/2, HOXB13).

Neurooncology (D.E. Matskо, M.V. Matsko, E.N. Imyanitov)

classification of CNS tumors, the degree of malignancy of the central nervous system tumors, molecular genetics, mutations in the gene IDH1/2, the co-deletion 1p19q, neurooncology